Dietary Phosphorus Restriction for Control of PTH in CKD Guideline 4.1. Restriction of Dietary Phosphorus in Patients with CKD  Dietary phosphorus should.

Slides:



Advertisements
Similar presentations
Assesment of renal function in case of near normal creatinine (<1
Advertisements

Essentials of CKD Comorbidities and outcomes in CKD.
Chronic Renal Failure in Cats: Can we Halt the Decline?
Learning objectives To understand the pathophysiologic basis for vasoactive therapies for HRS To become familiar with the diagnostic criteria for HRS To.
Streatham & Clapham Health Renal Outreach Clinic
LINEE GUIDA, KDIGO E DIALISI PERITONEALE
Kidney Disease-What You Need to Know
Chronic kidney disease
Chronic kidney disease
Hyperphosphataemia in chronic kidney disease Clinical case scenarios
ABC’s of Nephrology Sobha Malla RD,CSR 9/17/11
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
Prepared by D. Chaplin Chronic Renal Failure. Prepared by D. Chaplin Chronic Renal Failure Progressive, irreversible damage to the nephrons and glomeruli.
Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
The PREVEND Study: Screening for micro-albuminuria
West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients
Hasyim Kasim Syakib Bakri Hasanuddin university
Chronic Kidney Disease
General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.
REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
CKD FOR FINALS Dr H. Elcome, FY1 Dr K. Thompson, FY1.
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Monitoring Renal Disease Gary Coxon BVetMed MRCVS Veterinary Advisor Vetoquinol UK and Ireland.
+ Case Study One Pediatric Patient’s Experience Shelley Chapman RN, BSN, CCTC Children’s Hospital of Wisconsin.
Chronic Kidney Disease Workshop Maarten Taal Department of Renal Medicine Derby City General Hospital Derby Nephrology Research.
Chronic Kidney Disease (CKD)
Feast or Famine: Survival and Chronic Kidney Disease Kerin Worley and Deb Gipson UNC Chapel Hill April, 2004.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
I NTRODUCTION TO LABORATORY MEDICINE LECTURE 3. R ENAL PROFILE RENAL PANEL Glucose BUN Creatinine Potassium Phosphorous Sodium Albumin BUN/Creatinine.
Diseases of the Renal System KNH 413. CKD - Renal Replacement Therapy Hemodialysis (HD) or Peritoneal Dialysis (PD) Type based on underlying kidney disease.
Clinical Biochemistry FAQ for GP Trainees Dr Mourad Labib Consultant Chemical Pathologist DGOH NHS Foundation Trust July 2009.
Nutrition Considerations in CKD.  Management of the nutritional aspects CKD presents a number of challenges.  Malnutrition can occur in up 40% of patients.
Autopsy Findings. Important premortem finding Blood cultures positive for Escherichia coli Ascites fluid showed numerous neutrophils –negative for bacterial.
The National Kidney Foundation’s Kidney Early Evaluation Program TM “The Greater New York Experience” Ellen H. Yoshiuchi, MPS Division Program Director.
New Concepts in Chronic Kidney Disease Jonathan B. Jaffery, MD Assistant Professor of Medicine University of Wisconsin-Madison.
Chapter 9 Renal Disease. 2 Elsevier items and derived items © 2010, 2007 by Saunders, an imprint of Elsevier Inc. Learning Objectives  Describe the basic.
Taipei Medical University The Effect of Gender and Age on Nutritional Status of Hemodialysis Patients I ntroduction O bjective The prevalence of malnutrition.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Biochemical Test Serum Calcium
CKD Dr;BASHARDOOST. CKD –SOME DEFINITIONS IRREVERSIBLE LOSS OF GFR CKD results when a disease process damages the structural or functional integrity of.
Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:
A 57-year-old man presents with fatigue for several months. He underwent a blood transfusion with several units in 1982 after car accident. Physical examination.
Dietary Issues in Renal Complications Ulrich Wahl, Tamworth, 2010.
Dr. Aya M. Serry Renal Failure Renal failure is defined as a significant loss of renal function in both kidneys to the point where less than 10.
Anatomy Management of CKD LECTURE 10 Hazem.Kadhum Al-khafaji MD.FICMS Department of medicine Al-Qadissiah university.
Comparison of Asymmetric DimethylArginine Levels and Coronary Artery Calcifications in Different Stages of Chronic Kidney Disease and Kidney Transplantation.
1 Antonio Bellasi, MD Medical manager Genzyme, Italy Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD)
Blood Urea Nitrogen (BUN) T.A. Bahiya Osrah. Introduction Many factors can affect on kidney function leads to kidneys damage. –Diabetes –high blood pressure.
Lab (4): Renal Function test (RFT) Lecturer Nouf Alshareef KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab (Bioc 416) 2012
Lab (4): Renal Function test (RFT) Lecturers: Nouf Alshareef and Bahiya Osrah KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab.
Hyperphosphataemia in chronic kidney disease Support for education and learning for children and young people’s renal services: slide set March 2013 NICE.
Lab (5): Renal Function test (RFT) (Part 2) T.A Nouf Alshareef T.A Bahiya Osrah KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Serelaxin on Cardiac, Renal, and Hepatic.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Serelaxin on Cardiac, Renal, and Hepatic.
Lab (4): Renal Function test (RFT) T.A Nouf Alshareef and T.A. Bahiya Osrah KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab (Bioc.
The RBA/FLHSA High Blood Pressure Collaborative Baseline Data.
Presentation by JoAnn Czech RN/CDS St. Cloud Hospital.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
Lab (5): Renal Function test (RFT) (Part 2)
CARDIOVASCULAR CORELATIONS IN CHILDREN WITH END STAGE RENAL DISEASE
Copyright © 2015 by the American Osteopathic Association.
Figure 4 Interplay between acute kidney injury (AKI),
Ascites and Hepatorenal Syndrome: Pathophysiology and Management
End point Fenoldopam, n (%) Dopamine, n (%) p
Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina O'Shaughnessy et al. Am J Nephrol 2017;45:
Meeting the challenges of the new K/DOQI guidelines
Volume 74, Pages S88-S93 (December 2008)
Presentation transcript:

Dietary Phosphorus Restriction for Control of PTH in CKD Guideline 4.1. Restriction of Dietary Phosphorus in Patients with CKD  Dietary phosphorus should be restricted to mg/day when the serum phosphorus levels are elevated (>4.6 mg/dL [1.49 mmol/L] at stages 3 and 4 of CKD. Commentary  “The available data and the opinion of the Work Group support the proposal that dietary phosphate restriction should be initiated when blood PTH levels begin to rise (Stage 2) and/or when serum phosphorus levels are elevated at any stage of CKD.” Adapted from National Kidney Foundation. Am J Kidney Dis 2003;42(4 suppl 3):S2-S201.

Risk of Death by Quarterly Varying Phosphorus

SPD Study: Change from Baseline in Serum Phosphorus

Calciphylaxis: Case Study Patient: 64-year-old man with a history of cryptogenic cirrhosis. On admission the patient had:  Worsening liver failure  Hypotension  Renal failure Laboratory results: BUN:106 mg/dL (37.8 mmol/L) Creatinine:3.1 mg/dL (274.0 mmol/L) Total calcium:6.7 mg/dL (1.67 mmol/L) Phosphorus4.8 mg/dL (1.55 mmol/L) Calcium x phosphorous product32.2 mg 2 /dL 2 (2.58 mmol 2 /L 2 ) Albumin:1.3 g/dL (13 g/L) Blood, urine, and peritoneal fluid cultures were negative